Detection of TP53 mutation by DHPLC - IARC TP53 Database
Recommend Documents
introduced by means of a vector inside mamma- lian, insect, plant, or ...... Liposomes are vesicular particles composed of a lipid bilayer enclosing a ...... the use of retroviruses or lentiviruses to stably transduce skin ..... CYP3A4/5. CYP3A4/5.
These findings demonstrate that mutation at R249 of TP53 can be considered for increasing risk ... 248, 249, 273, and 282 cause distortions that create internal.
This study was supported by a grant from the Korea Health. Technology ... 47:421-8. 4. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI,.
carcinoma may yield important insights into the pathogenesis of this entity and provide a .... The top 10 genes most overexpressed in the small cell component ...
Oct 10, 2016 - Aberrant p53 function, due to 17p deletion (del(17p)) and/or TP53 mutation, is associated with poor prognosis in chronic lymphocytic leukemia ...
Apr 14, 2016 - Moscinski LC, List AF, and Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome ...
Dec 24, 2015 - patients with transitional cell carcinoma of urinary bladder .... papillary neoplasm with low grade of malignancy; (C) grade III, low grade of papillary carcinoma; (D) .... potential, low grade, and high grade papillary carcinoma),.
Apr 3, 2017 - Stang A. Critical evaluation of the Newcastle-Ottawa scale for the ... Stefancikova L, Moulis M, Fabian P, Ravcukova B, Vasova I, Muzik J, et al.
Results 24 - 617 - implicated in various tumors, the role of TP53 mutation in the development of FNH is ..... papillary urothelial neoplasm of low malignant potential.
Dec 1, 2008 - sequencing TP53 exon 10 in 123 women with breast cancer and 223 age- and .... a grandson with adrenocortical carcinoma at age 18 months.
Feb 9, 2011 - Abstract LiâFraumeni syndrome (LFS) is a rare familial cancer syndrome characterized by early cancer onset, diverse tumor types, and multiple ...
Jan 11, 2007 - Clinical significance of TP53 mutation in myeloma. Leukemia (2007) 21, 582â584. doi:10.1038/sj.leu.2404524; published online 11 January ...
Type of TP53 mutation. Number of patients with the mutation. Exon c.375G>A (p?) 1. 4 c.404G>T (p.C135F). 2. 5 c.422G>A (p.C141Y). 1. 5 c.423C>G (p.C141W).
Jul 15, 2016 - drosarcoma area only, suggesting an important role for TP53 mutation in this ... malignant transformation, fibrous dysplasia, GNAS, TP53.
TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco ... Tel: 33 4 72738532; Fax: 33 4 72738322; Email: [email protected].
Mar 26, 2018 - Landers, J. E., D. S. Haines, J. F. Strauss, 3rd and D. L. George (1994). ... Savage, J., E. Adams, E. Veras, K. M. Murphy and B. M. Ronnett ...
Jan 11, 2007 - homeostasis, and its inactivation at the gene or protein level ... TP53 mutations in newly diagnosed myeloma patients by screening genomic ...
Mar 15, 2015 - She was being treated with gefitinib for lung adenocarci- ... that might explain the acquired resistance to gefitinib could not be found in.
IGHV mutation status. IGHV mutational status was investigated as previously reported. 17. Sequences were aligned to the. ImMunoGeneTics sequence directory ...
May 8, 2014 - to a range of cancers, most commonly sarcoma, brain tumours and ... JA holds a Great Ormond Street Hospital Charity Leadership Award and.
Jun 4, 2012 - Aflatoxin-Induced TP53 R249S Mutation in. HepatoCellular Carcinoma in Thailand: Association with. Tumors Developing in the Absence of ...
Aug 25, 2016 - Keywords: glycolytic efficiency, breast cancer, Warburg effect, next generation ... metabolism first observed by Otto Warburg in 1956 involves ...
May 22, 2018 - [3] Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in pre- ... 2018;4:351â7. [22] Yarchoan M, Hopkins A, Jaffee EM.
Detection of TP53 mutation by DHPLC - IARC TP53 Database
PCR conditions for amplifying genomic DNA sequences within exons 2-11 of .... (G50-Pharmacia-Millipore). Program: 96°C. 10 sec. 50°C. 5 sec. 60°C. 4 min.
Detection of TP53 mutations by direct sequencing (IARC protocol, 2010 update) PCR conditions PCR conditions for amplifying genomic DNA sequences within exons 2-11 of human TP53 gene are summarized in the following table. Depending on the quality of your DNA template, you may use primer pairs that amplify large (good DNA quality) or small (poor DNA quality) fragments. Nucleotides highlighted in yellow have been described as site of polymorphisms (should not affect PCR according to our experience).
IARC code
Primer pairs (5’ 3’)
Direction
Region amplified
Product length
PCR program
PCR mix
P-559 P-E3Ri
tctcatgctggatccccact agtcagaggaccaggtcctc
F R
Exons 2-3
344 bp
A or B
1
P-329 P-330
tgctcttttcacccatctac atacggccaggcattgaagt
F R
Exon 4
353 bp
B
1
P-326 P-327
tgaggacctggtcctctgac agaggaatcccaaagttcca
F R
Exon 4
413 bp
B
1
P-312 P-271
ttcaactctgtctccttcct cagccctgtcgtctctccag
F R
Exon 5
248 bp
B
1
P-239 P-240
gcctctgattcctcactgat ttaacccctcctcccagaga
F R
Exon 6
181 bp
B
1
P-236 P-240
tgttcacttgtgccctgact ttaacccctcctcccagaga
F R
Exons 5-6
467 bp
B
1
P-333 P-313
cttgccacaggtctccccaa aggggtcagaggcaagcaga
F R
Exon 7
237 bp
C
2
P-237 P-238
aggcgcactggcctcatctt tgtgcagggtggcaagtggc
F R
Exon 7
177 bp
B
1
P-316 P-319
ttccttactgcctcttgctt aggcataactgcacccttgg
F R
Exon 8
231 bp
B
1
P-314 P-315
ttgggagtagatggagcct agtgttagactggaaacttt
F R
Exons 8-9
445 bp
B
1
9F 9R
gacaagaagcggtggag cggcattttgagtgttagac
F R
Exon 9
215
E
1
P-E10Li P-562
caattgtaacttgaaccatc ggatgagaatggaatcctat
F R
Exon 10
260 bp
D
1
P-E11Le P-E11Re
agaccctctcactcatgtga tgacgcacacctattgcaag
F R
Exon 11
245 bp
B
1
PCR mix 1. GoTaq Hot Start Polymerase (Promega)
Components
Volume/reaction
Final concentration
- 5X PCR buffer without MgCl2
4 µl
1X
- 25mM MgCl2
1.2 µl
1.5mM
- dNTP mix (5mM each)
0.8 µl
0.2mM each
- Primer, forward 10µM
0.8 µl
0.4µM
- Primer, reverse 10 µM
0.8 µl
0.4µM
- GoTaq DNA polymerase (5U/ul)
0.1 µl
0.5 U
- Template DNA
50 ng
- Water, molecular biology grade
Qsp 20 µl
2. HotStarTaq (Qiagen)
Components
Volume/reaction
Final concentration
- 10X PCR buffer containing 15 mM MgCl2
2 µl
1X
- 5X Q-Solution
4 µl
1X
- dNTP mix (5mM each)
0.8 µl
0.2 mM each
- Primer, forward 10uM
0.8 ul µl
0.4 µM
- Primer, reverse 10 uM
0.8 µl
0.4 µM
- HotStarTaq DNA polymerase (5U/µl)
0.1 µl
0.5 U
- Template DNA
50 ng
- Water, molecular biology grade
Qsp 20 µl
PCR programs
A:
50 cycles
72°C
94°C
94°C
2 min
30 sec
72°C 61°C
Keep at 10°C
10 min
45 sec
45 sec
B: 30 cycles
20 cycles
94°C 2 min
94°C
94°C 72°C
30 sec 63°C
30 sec 60°C
1 min
45 sec
72°C
72°C
1 min
10 min
Keep at 10°C
45 sec
- 0.5°C every 3 cycles
C: 50 cycles
72°C
95°C
94°C
15 min
30 sec
72°C 60°C
Keep at 10°C
10 min
30 sec
30 sec
D: 30 cycles
20 cycles
94°C 2 min
94°C
94°C 72°C
30 sec 58.5°C
1 min
45 sec - 0.5°C every 3 cycles
30 sec 55°C 45 sec
72°C
72°C
1 min
10 min
Keep at 10°C
E:
50 cycles
94°C 2 min
72°C
94°C 30 sec
72°C
57° C 61°C
Keep at 10°C
10 min
45 sec sec 30
45 30sec sec
Purification of PCR products Prior sequence analysis, 5 µl of PCR products are purified with the enzyme ExoSapIT (USB) for15 min at 37°C and 15 min at 80°C. You may also use: - columns (i.e. QIAquick PCR Purification kit, QIAGEN) - plates (i.e. NucleoFast 96 PCR kit, Clontech) TP53 sequencing Sequencing is performed by IARC common sequencing service. Sequencing reaction Sequencing reaction is done with BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) according to the following protocol: Mix:
Program:
-
7 µl of purified PCR product
-
1.25µl Buffer
-
0.5µl primer 10µM*
-
1.5µl Big Dye
96°C
10 sec
50°C
5 sec
60°C
4 min
30 cycles
* Same primers as the ones used for PCR amplification reactions (note that R primer for exon 11 does not work well for sequencing). Purification of sequencing reaction Before analysis, purification of the sequencing reaction products is done by the Sequencing Service with 96-well Multiscreen filtration plates (G50-Pharmacia-Millipore).
Sequencing analysis PCR products are analyzed by a 16-capillary automated sequencer (ABI PRISM® 3100 Genetic Analyzer, Applied Biosystems), based on the Sanger method (see principle at: http://www.bio.davidson.edu/Courses/Molbio/MolStudents/spring2003/Obenrader/sanger_ method_page.htm)
Result analysis and interpretation Chromatograms are analyzed semi-automatically by visual inspection of sequences imported in a sequence analysis software using the reference sequence, NC_000017.9 (hg18 built), from Genbank (http://www-p53.iarc.fr/TP53sequence_NC_000017-9.html). Variations are analyzed with the IARC TP53 database (http://www-p53.iarc.fr), to check whether the variation is a known polymorphism or a mutation, and get frequency and functional data for each specific variation.
